Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $443,400.00 in Stock

Key Points

• Insider sale: Brian Webster sold 15,000 Kestra Medical Technologies shares for $443,400, reducing his direct stake by 3.26% to 445,215 shares. This follows several additional insider sales since late July.
• Stock performance and fundamentals: KMTS rose 3.7% to $28.32, near its 52-week high of $30.00. However, the company missed quarterly earnings expectations, reporting a loss of $0.75 per share versus the $0.61 consensus estimate, and remains unprofitable.
• Analyst outlook: Analysts maintain a consensus “Moderate Buy” rating with an average price target of $29.00; Evercore initiated coverage with an “outperform” rating and a $34 target.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Webster sold 15,000 shares of the firm's stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $29.56, for a total value of $443,400.00. Following the transaction, the insider directly owned 445,215 shares of the company's stock, valued at $13,160,555.40. This represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 17th, Brian Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $27.48, for a total value of $412,200.00.
• On Tuesday, August 4th, Brian Webster sold 51,900 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.52, for a total value of $1,272,588.00.
• On Monday, August 3rd, Brian Webster sold 13,017 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.92, for a total transaction of $311,366.64.
• On Friday, July 31st, Brian Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
• On Thursday, July 30th, Brian Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total transaction of $178,511.04.

Kestra Medical Technologies Stock Up 3.7%

KMTS traded up $1.01 during trading on Thursday, reaching $28.32. 739,134 shares of the stock traded hands, compared to its average volume of 349,841. The stock's 50-day simple moving average is $26.40 and its two-hundred day simple moving average is $23.73. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. Kestra Medical Technologies, Ltd. has a fifty-two week low of $17.34 and a fifty-two week high of $30.00. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -10.61 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.14). The business had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. As a group, equities research analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Wednesday, July 15th. Evercore started coverage on Kestra Medical Technologies in a research report on Tuesday. They set an "outperform" rating and a $34.00 target price on the stock. Piper Sandler restated an "overweight" rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Finally, Weiss Ratings raised Kestra Medical Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, September 16th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $29.00.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LP raised its stake in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company's stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company's stock worth $4,726,000 after acquiring an additional 43,753 shares during the period. Spartan Wealth Advisory Services LLC acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter valued at about $603,000. Bank of New York Mellon Corp boosted its position in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company's stock valued at $1,397,000 after acquiring an additional 22,471 shares in the last quarter. Finally, Quantinno Capital Management LP bought a new stake in Kestra Medical Technologies in the first quarter valued at about $431,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient's heart rhythm and deliver a therapeutic shock when clinically necessary.

The company's platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.